SCHEMBL17599395

SCHEMBL17599395

CCCCCCCCn1nc(C)c(S(=O)(=O)Nc2ccc(-c3cc(C(=O)O)ccc3F)c3ncccc23)c1C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.37
▸ KEAP1 Q14145 1/20 0.36
▸ GLO1 Q04760 1/20 0.36
▸ MMP2 P08253 2/20 0.36
▸ MMP9 P14780 1/20 0.36
▸ SLC40A1 Q9NP59 1/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ FABP4 P15090 5/20 0.35
▸ FABP5 Q01469 5/20 0.35
▸ RORC P51449 5/20 0.35
▸ SLC16A3 O15427 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17613353 0.91 FABP4 (0.38) SMN1; SMN2FABP4FABP5
SCHEMBL17599375 0.80 ACLY (0.49) KDM4EKEAP1GLO1MMP2MMP9
SCHEMBL17599385 0.76 TSHR (0.47) SMN1; SMN2FABP4FABP5SLC16A3KMT2A
SCHEMBL17599320 0.74 SMN1; SMN2 (0.54) KDM4ETDP1HTTSMN1; SMN2FABP4
SCHEMBL17599357 0.73 KDM4E (0.46) KDM4EGLO1MMP2MMP9SLC40A1
SCHEMBL17599338 0.73 FABP4 (0.42) SMN1; SMN2FABP4FABP5SLC16A3
SCHEMBL17612856 0.72 KEAP1 (0.56) KDM4EKEAP1ALDH1A1GAAHTT
SCHEMBL17599305 0.72 ACLY (0.55) SMN1; SMN2FABP4FABP5SLC16A3
SCHEMBL17599334 0.71 PFKFB4 (0.41) KDM4EGLO1MMP2MMP9SLC40A1
SCHEMBL17599377 0.71 PFKFB3 (0.56) KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998294-A1 Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback